The Importance of Countering Biosimilar Disparagement and Misinformation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Importance of Countering Biosimilar Disparagement and Misinformation
Authors
Keywords
-
Journal
BIODRUGS
Volume 34, Issue 4, Pages 407-414
Publisher
Springer Science and Business Media LLC
Online
2020-07-20
DOI
10.1007/s40259-020-00433-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
- (2020) Liese Barbier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients
- (2019) Lieven Pouillon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
- (2019) Yifei Liu et al. ADVANCES IN THERAPY
- The effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch
- (2019) Chiara Gasteiger et al. ARTHRITIS CARE & RESEARCH
- Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow-up survey
- (2019) Laurent Peyrin-Biroulet et al. United European Gastroenterology Journal
- Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
- (2019) Binita Dutta et al. BIODRUGS
- Overcoming barriers to biosimilars in inflammatory arthritis
- (2019) Jonathan Kay Nature Reviews Rheumatology
- Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
- (2018) Ross A. McKinnon et al. BIODRUGS
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
- (2018) Hillel P. Cohen et al. DRUGS
- Maintaining consistent quality and clinical performance of biopharmaceuticals
- (2018) William C. Lamanna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- American Society of Clinical Oncology Statement: Biosimilars in Oncology
- (2018) Gary H. Lyman et al. JOURNAL OF CLINICAL ONCOLOGY
- The Science Behind Biosimilars
- (2018) S. Louis Bridges et al. Arthritis & Rheumatology
- Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
- (2018) Mourad F. Rezk et al. ADVANCES IN THERAPY
- Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease
- (2018) Laura E. Raffals et al. Clinical Gastroenterology and Hepatology
- Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice
- (2018) Niels S. Vermeer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Internet Health Information Seeking and the Patient-Physician Relationship: A Systematic Review
- (2017) Sharon Swee-Lin Tan et al. JOURNAL OF MEDICAL INTERNET RESEARCH
- The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference
- (2017) Judy Crespi-Lofton et al. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
- (2016) Hillel Cohen et al. ADVANCES IN THERAPY
- Building a wall against biosimilars
- (2013) NATURE BIOTECHNOLOGY
- Biosimilars: what clinicians should know
- (2012) M. Weise et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now